Chronic Elevation of Systemic Glucagon-Like Peptide-1 Following Surgical Weight Loss: Association with Nausea and Vomiting and Effects on Adipokines
نویسندگان
چکیده
We determined whether persistent nausea and vomiting (N/V) symptoms following Roux-en-Y gastric bypass surgery is due to elevated systemic glucagon-like peptide-1 (GLP-1) and leptin in female non-diabetic subjects. Subjects with N/V post-Roux-en-Y gastric bypass (RYGB) surgery had significantly elevated fasting GLP-1 levels compared to that with post-operative asymptomatic subjects and to morbidly obese, obese and lean subjects not undergoing surgery. Weight loss, glycaemia, insulin and post-prandial GLP-1 levels were similar in all post-operative subjects. Despite comparable BMI, leptin was significantly lower in symptomatic subjects. Furthermore, leptin secretion from subcutaneous adipose tissue was inhibited by GLP-1 (0.1-1.0 nM; n = 6). Persistent N/V following RYGB surgery is associated with elevated fasting GLP-1, but lower leptin levels. The latter may be a consequence of the direct GLP-1 inhibition of leptin secretion from adipose tissue.
منابع مشابه
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
OBJECTIVE To determine whether treatment with agonists of glucagon-like peptide-1 receptor (GLP-1R) result in weight loss in overweight or obese patients with or without type 2 diabetes mellitus. DESIGN Systematic review with meta-analyses. DATA SOURCES Electronic searches (Cochrane Library, Medline, Embase, and Web of Science) and manual searches (up to May 2011). Review methods Randomised...
متن کاملExenatide: a novel treatment of Type 2 diabetes
10.2217/14750708.2.2.207 © 2 part of Glucagon-like peptide-1 is an incretin hormone with antidiabetic action due to stimulation of insulin secretion, and potentially also to an increase in β-cell mass, inhibition of glucagon secretion, delay in gastric emptying and induction of satiety. A problem in developing glucagon-like peptide-1 as a therapeutic compound is that the hormone is rapidly inac...
متن کاملA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight gain. Glucagon-like peptide-1 (GLP-1) receptor agonists represent a unique approach to the treatment of diabetes, with benefits extending outside glucose control, including positive effects on weight, blood pressure, ...
متن کاملGLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases.
BACKGROUND Patients with hypothalamic pathology often develop morbid obesity, causing severe metabolic alterations resulting in increased morbidity and mortality. Glucagon-like peptide-1 (GLP-1) analogues improve glycaemic control in type 2 diabetic patients and cause weight loss in obese patients by yet unknown mechanisms. Here we tested whether GLP-1 analogues were also effective in the treat...
متن کاملEFFECTS OF AEROBIC TRAINING ON DIPEPTIDYL PEPTIDASE-4 AND GLUCAGON-LIKE PEPTIDE-1 IN OBESE WOMEN WITH TYPE 2 DIABETES
Background: Obesity increases the risk of developing type 2 diabetes with regard to the hormones involved. The purpose of this quasi-experimental study was to investigate the effect of aerobic exercise on Dpp-4 and GLP-1 in obese women with type 2 diabetes. Methods: From among obese women with type-2 diabetes mellitus 35-50 years old referred to the Diabetes Association of Saveh, 20 people wer...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 25 شماره
صفحات -
تاریخ انتشار 2015